Enlivex Therapeutics Ltd.
ENLV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $25,007 | $26,718 | $21,243 | $25,617 |
| - Cash | $4,196 | $1,892 | $2,053 | $3,301 |
| + Debt | $701 | $480 | $503 | $534 |
| Enterprise Value | $21,512 | $25,306 | $19,693 | $22,850 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$81 | -$85 | -$90 | -$36 |
| % Margin | – | – | – | – |
| EBITDA | -$2,124 | -$2,993 | -$3,414 | -$5,140 |
| % Margin | – | – | – | – |
| Net Income | -$2,205 | -$1,868 | -$3,452 | -$5,176 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.092 | -0.078 | -0.16 | -0.24 |
| % Growth | -17.1% | 51.1% | 33.3% | – |
| Operating Cash Flow | -$2,295 | -$1,198 | -$4,624 | -$4,117 |
| Capital Expenditures | -$24 | -$7 | -$32 | -$35 |
| Free Cash Flow | -$2,319 | -$1,205 | -$4,656 | -$4,153 |